Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials

Journal of Bone and Mineral Research

Volumn 28, Issue 6, 2013, Pages 1348-1354

  Schwartz, Ann V ^a   Schafer, Anne L ^a,b   Grey, Andrew ^c   Vittinghoff, Eric ^a   Palermo, Lisa ^a   Lui, Li Yung L ^d   Wallace, Robert B ^e   Cummings, Steven R ^d   Black, Dennis M ^a   Bauer, Douglas C ^a   Reid, Ian R ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

ANTIRESORPTIVE THERAPY; DIABETES; GLUCOSE; WEIGHT

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; GLUCOSE; PLACEBO; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BODY WEIGHT; BONE MASS; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; DIABETES MELLITUS; FAT MASS; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OBESITY; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY EFFECT; WEIGHT CHANGE; WEIGHT GAIN;

AGED; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; BONE DENSITY CONSERVATION AGENTS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; FASTING; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; INCIDENCE; INSULIN RESISTANCE; MICE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 84877936820     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1865     Document Type: Article

References (36)

1. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G., Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010; 142: 296-308.
2. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G., Endocrine regulation of energy metabolism by the skeleton. Cell. 2007; 130: 456-69.
3. Lian JB, Gundberg CM., Osteocalcin. Biochemical considerations and clinical applications. Clin Orthop. 1988; 226: 267-91.
4. Gundberg CM, Lian JB, Booth SL., Vitamin K-dependent carboxylation of osteocalcin: friend or foe?. Adv Nutr. 2012; 3: 149-57.
5. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E., Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002; 87: 985-92.
6. Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR., The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2009; 94: 538-44.
7. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman RE, Paterson AH, Gao GM, Kinsey AC, Peterson MC, Jun S., Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res. 2008; 14: 6690-6.
8. Schafer AL, Sellmeyer DE, Schwartz AV, Rosen CJ, Vittinghoff E, Palermo L, Bilezikian JP, Shoback DM, Black DM., Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH Study). J Clin Endocrinol Metab. 2011; 96: 1982-9.
9. Ferron M, Hinoi E, Karsenty G, Ducy P., Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA. 2008; 105: 5266-70.
10. Motyl KJ, McCabe LR, Schwartz AV., Bone and glucose metabolism: a two-way street. Arch Biochem Biophys. 2010; 503: 2-10.
11. Pittas AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B., Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrin Metab. 2008; 94: 827-32.
12. Yoshida M, Jacques PF, Meigs JB, Saltzman E, Shea MK, Gundberg C, Dawson-Hughes B, Dallal G, Booth SL., Effect of vitamin K supplementation on insulin resistance in older men and women. Diabetes Care. 2008; 31: 2092-6.
13. Shea MK, Gundberg CM, Meigs JB, Dallal GE, Saltzman E, Yoshida M, Jacques PF, Booth SL., Gamma-carboxylation of osteocalcin and insulin resistance in older men and women. Am J Clin Nutr. 2009; 90: 1230-5.
14. Ngarmukos C, Chailurkit LO, Chanprasertyothin S, Hengprasith B, Sritara P, Ongphiphadhanakul B., A reduced serum level of total osteocalcin in men predicts the development of diabetes in a long-term follow-up cohort. Clin Endocrinol (Oxf). 2012; 77: 42-6.
15. Hwang YC, Jee JH, Jeong IK, Ahn KJ, Chung HY, Lee MK., Circulating osteocalcin level is not associated with incident type 2 diabetes in middle-aged male subjects: mean 8.4-year retrospective follow-up study. Diabetes Care. 2012; 35: 1919-24.
16. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR., Design of the Fracture Intervention Trial. Osteoporos Int. 1993; 3: S29-S39.
17. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348: 1535-1541.
18. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ., Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280: 2077-82.
19. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR., Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809-22.
20. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C., Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 756-65.
21. Fleiss JL., Statistical methods of rates and proportions. 2nd ed. New York: John Wiley & Sons; 1981.
22. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD., Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial. J Bone Miner Res. 2004; 19: 1250-8.
23. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R., Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009; 24: 1544-51.
24. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD., Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994; 79: 1693-700.
25. Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H., Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab. 2008; 26: 260-4.
26. Aonuma H, Miyakoshi N, Hongo M, Kasukawa Y, Shimada Y., Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption. Tohoku J Exp Med. 2009; 218: 201-5.
27. Ogden CL, Carroll MD, Flegal KM., Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am. 2003; 32: 741-60 vii.
28. McBean AM, Li S, Gilbertson DT, Collins AJ., Differences in diabetes prevalence, incidence, and mortality among the elderly of four racial/ethnic groups: whites, blacks, Hispanics, and Asians. Diabetes Care. 2004; 27: 2317-24.
29. Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K., The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia. 2008; 51: 2187-96.
30. Demakakos P, Marmot M, Steptoe A., Socioeconomic position and the incidence of type 2 diabetes: the ELSA study. Eur J Epidemiol. 2012; 27: 367-78.
31. Vestergaard P., Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate. Calcif Tissue Int. 2011; 89: 265-70.
32. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282: 637-45.
33. Barrett-Connor E, Ensrud KE, Harper K, Mason TM, Sashegyi A, Krueger KA, Anderson PW., Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther. 2003; 25: 919-30.
34. Kumar R, Binkley N, Vella A., Effect of phylloquinone supplementation on glucose homeostasis in humans. Am J Clin Nutr. 2010; 92: 1528-32.
35. Wedick NM, Barrett-Connor E, Knoke JD, Wingard DL., The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: the Rancho Bernardo study. J Am Geriatr Soc. 2002; 50: 1810-5.
36. Bolland MJ, Grey AB, Gamble GD, Reid IR., Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab. 2010; 95: 1174-81.